Equillium, Inc.
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Non-accelerated filerSmaller reporting company
State of Incorporation
DE
Business Address
2223 AVENIDA DE LA PLAYA, LA JOLLA, CA, 92037
Mailing Address
2223 AVENIDA DE LA PLAYA, LA JOLLA, CA, 92037
Phone
(858) 412-5302
Fiscal Year End
1231
EIN
821554746
Financial Overview
FY2025
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 10-K Annual financial report | March 25, 2026 | View on SEC |
| 8-K Current report of material events | March 25, 2026 | View on SEC |
| SCHEDULE 13G Passive beneficial ownership (>5%) | March 20, 2026 | View on SEC |
| 4 Insider stock transaction report | March 16, 2026 | View on SEC |
| 8-K Current report of material events | March 13, 2026 | View on SEC |
| 4/A Insider transaction amendment | March 11, 2026 | View on SEC |
| 4 Insider stock transaction report | March 11, 2026 | View on SEC |
| 4 Insider stock transaction report | February 23, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | February 6, 2026 | View on SEC |
| 4 Insider stock transaction report | January 9, 2026 | View on SEC |
Annual Reports
10-K
March 25, 2026
- Advancing EQ504 for inflammatory diseases with human trials targeted for mid-2026.
- Developing EQ302 as an oral treatment for celiac disease and autoimmune disorders.
Insider Trading
STRONG SELL
2 insiders
10 recent transactions
View Full Insider Trading Profile
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.